Henry Gosebruch joined Galapagos as Chief Executive Officer and member of the Board of Directors on May 12, 2025. Prior to Galapagos, Henry served as President and CEO of Neumora (NASDAQ: NMRA), a clinical-stage biopharmaceutical company focused on neuroscience. Under his leadership, Neumora advanced multiple clinical programs and built strong development capabilities. Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie, where his responsibilities included corporate strategy, alliance management, business development, and M&A, contributing to the company’s significant growth, pipeline expansion and diversification. Before AbbVie, he spent over 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group. Henry currently serves on the Board of Directors at Acelyrin (NASDAQ: SLRN) and on the Advisory Board of the Life Sciences & Management Program at the University of Pennsylvania
